Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan ...Middle East

TOKYO, April 7, 2024 /PRNewswire/ -- Renalys Pharma, Inc. (Headquarters: Chuo-ku, Tokyo; "Renalys Pharma") announced that it has submitted an Investigational New Drug (IND) Application for sparsentan to the Pharmaceuticals and Medical Devices Agency (PMDA) for a Phase III clinical trial...

Hence then, the article about renalys pharma submits an ind application for a phase iii clinical trial of sparsentan for iga nephropathy in japan was published today ( Monday 08/04/2024 - 04:05 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Renalys Pharma Submits an IND Application for a Phase III Clinical Trial of sparsentan for IgA Nephropathy in Japan )

Also on site :

• PRIVACY ALERT: Abbott Laboratories and Exact Sciences Corporation Under Investigation for Data Breach of Patient Records
• Amazon’s ‘Breathable’ Athletic Skort Is a Tenniscore Staple That’s Perfect for Sports, Travel, and Errands
• Capri Pants Are on Trend for 2026 — Snag a Quick-Drying Cargo Pair That's ‘Perfect for Summer’ at Walmart